omniture
上海复宏汉霖生物技术股份有限公司 Henlius

Latest News

Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer

SHANGHAI, April 7, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...

2022-04-07 22:21 4361

Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG

SHANGHAI, March 25, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that it...

2022-03-25 21:24 6770

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the yea...

2022-03-17 08:00 5200

Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma

SHANGHAI, March 16, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the yea...

2022-03-16 23:46 2732

Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population

* The ASTRUM-005 states that serplulimab combined with carboplatin-etoposide prolonged median OS ...

2021-12-20 22:00 3438

Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the ...

2021-12-08 08:30 4239

Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration

SHANGHAI, Dec. 4, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that beva...

2021-12-04 01:51 7233

Henlius Novel Anti PD-L1/TIGIT Bispecific Antibody Received Clinical Trial Approval in Australia

SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the...

2021-11-25 17:27 4787
1234